Data protection Impressum

Newsroom

The Munich- and Lausanne-based biotech secures Europe’s largest-ever Series C financing to accelerate development of next-generation antibody-drug conjugates.

Tubulis raises EUR 308 million to advance ADC therapies and expand its clinical pipeline

29 October 2025

The transaction marks a major milestone for the Vaud-based software company, reinforcing its leadership in AI-powered Digital Employee Experience solutions.

Vista Equity Partners acquires majority stake in Nexthink in USD 3 billion deal

29 October 2025

A world-class ecosystem where research, education, and industry converge to shape the future of sustainable production.

Fribourg, Switzerland’s hub for digital manufacturing

Switzerland leads the Eight Competitiveness Report 2025, topping 58 nations for its ability to balance prosperity, trust, education, and sustainability.

Switzerland named the world’s most competitive country in 2025

27 October 2025

Neuchâtel-based start-up Symactiv has won the 2025 BCN Innovation Prize and CHF 150,000 for its biofertilizer pellets designed to restore soil health and productivity.

Symactiv wins the 2025 BCN Innovation Prize for its sustainable soil regeneration technology

27 October 2025

Neurotechnology company ONWARD Medical extends its cash runway through 2026 and prepares to expand commercialization and clinical development of its ARC Therapy systems.

ONWARD Medical raises over EUR 50 million to advance spinal cord therapies

27 October 2025

Adaptyv raises USD 8 million to accelerate AI-powered protein validation

27 October 2025

Switzerland leads the Global Investment Risk and Resilience Index, reflecting its exceptional stability, innovation capacity, and governance quality.

Switzerland ranked world’s most secure country for investment

27 October 2025

Vaud-based FemTech company Aspivix begins commercial rollout in Southern California and New York following strong clinical validation and growing U.S. demand.

Aspivix launches its breakthrough Carevix device in the United States

21 October 2025

Lausanne-based biotech ADC Therapeutics has secured USD 60 million in new financing to expand commercialization of its cancer treatment ZYNLONTA.

ADC Therapeutics raises USD 60 million to strengthen oncology portfolio

21 October 2025

1 2 3 4 5 6 7 8 9 … 153